Cover Image
市場調查報告書

原發性膽汁性肝硬化(PBC) : 開發平台分析

Primary Biliary Cirrhosis - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 200481
出版日期 內容資訊 英文 90 Pages
訂單完成後即時交付
價格
Back to Top
原發性膽汁性肝硬化(PBC) : 開發平台分析 Primary Biliary Cirrhosis - Pipeline Review, H2 2016
出版日期: 2016年07月13日 內容資訊: 英文 90 Pages
簡介

原發性膽汁型肝硬化(PBC)是肝臟的慢性疾病,因自體免疫性造成惡化性膽汁淤積,有時一直惡化到肝臟疾病末期。PBC的患者幾乎皆為女性,此外50∼60歲發病病例最多。

本報告提供全球各國治療原發性膽汁性肝硬化(以下簡稱PBC)用的開發中產品之開發情形相關分析,提供您開發中產品的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要(產品概要,功能機制,研究開發(R&D)的發展情形),最新的產業趨勢等調查結果。

簡介

  • 分析範圍

原發性膽汁性肝硬化(PBC)概要

治療藥的開發

  • PBC開發中產品:概要
  • PBC開發中產品:比較分析

各企業開發中的PBC治療藥

大學/研究機關研究中的PBC治療藥

開發中產品的概要

  • 最後階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

PBC治療藥:開發中的產品一覽(各企業)

PBC開發治療藥的企業

  • AlbireoPharma
  • CymaBay Therapeutics, Inc.
  • Dr. Falk Pharma GmbH
  • Enanta Pharmaceuticals, Inc.
  • GlaxoSmithKline Plc
  • Intercept Pharmaceuticals, Inc.
  • Johnson & Johnson
  • MediGene AG
  • NGM Biopharmaceuticals, Inc.
  • Virobay Inc.

原發性膽汁性肝硬化(PBC):治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各行動機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • A-4250
  • budesonide
  • FFP-104
  • GSK-2330672
  • MBX-8025
  • NGM-282
  • obeticholic acid
  • RhuDex
  • Small Molecules to Agonize Farnesoid X Receptor for Non-alcoholic Steatohepatitis and Primary Biliary Cirrhosis
  • ustekinumab
  • VBY-825

PBC治療藥:最新的藥物簡介

PBC相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8270IDB

Summary

Global Markets Direct's, 'Primary Biliary Cirrhosis - Pipeline Review, H2 2016', provides an overview of the Primary Biliary Cirrhosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Primary Biliary Cirrhosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Primary Biliary Cirrhosis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Primary Biliary Cirrhosis
  • The report reviews pipeline therapeutics for Primary Biliary Cirrhosis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Primary Biliary Cirrhosis therapeutics and enlists all their major and minor projects
  • The report assesses Primary Biliary Cirrhosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Primary Biliary Cirrhosis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Primary Biliary Cirrhosis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Primary Biliary Cirrhosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
    • Primary Biliary Cirrhosis Overview
    • Therapeutics Development
  • Pipeline Products for Primary Biliary Cirrhosis - Overview
  • Primary Biliary Cirrhosis - Therapeutics under Development by Companies
  • Primary Biliary Cirrhosis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Primary Biliary Cirrhosis - Products under Development by Companies
  • Primary Biliary Cirrhosis - Companies Involved in Therapeutics Development
    • AlbireoPharma
    • CymaBay Therapeutics, Inc.
    • Dr. Falk Pharma GmbH
    • Enanta Pharmaceuticals, Inc.
    • Genextra S.p.a.
    • GenKyoTex S.A.
    • GlaxoSmithKline Plc
    • MediGene AG
    • NGM Biopharmaceuticals, Inc.
    • Novartis AG
    • Shire Plc
    • TGV-Laboratories
    • Virobay Inc.
  • Primary Biliary Cirrhosis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • A-4250 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • budesonide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EDP-305 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FFP-104 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GKT-831 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-2330672 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Hep-114 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LJN-452 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • maralixibat chloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MBX-8025 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NGM-282 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • obeticholic acid - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RhuDex - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VBY-825 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Primary Biliary Cirrhosis - Dormant Projects
  • Primary Biliary Cirrhosis - Product Development Milestones
    • Featured News & Press Releases
      • May 31, 2016: CymaBay Therapeutics Announces Top Line Efficacy and Safety Data From Its Phase 2 Study of Mbx-8025 in Patients With Primary Biliary Cholangitis (PBC)
      • May 27, 2016: FDA Grants Accelerated Approval to Ocaliva (Obeticholic Acid) for the Treatment of Patients with PBC
      • May 18, 2016: Intercept Announces Ocaliva (Obeticholic Acid) Data in PBC to be Presented at DDW 2016
      • Apr 14, 2016: New Analyses of the Phase 3 POISE Trial of Ocaliva (Obeticholic Acid) for the Treatment of PBC Presented at EASL
      • Apr 07, 2016: FDA Advisory Committee Unanimously Recommends Accelerated Approval of Ocaliva (obeticholic acid) for the Treatment of PBC
      • Mar 30, 2016: Intercept Announces New OCA Data in PBC and NASH to be Presented at EASL 2016
      • Feb 03, 2016: Fast Forward Pharmaceuticals Initiates Phase II Pilot Studies in Primary Biliary Cirrhosis and Crohn's Disease with anti-CD40 Monoclonal Antibody
      • Dec 17, 2015: FDA Extends PDUFA Date for Obeticholic Acid for the Treatment of PBC
      • Nov 14, 2015: Intercept Presents New PBC Data at AASLD 2015
      • Nov 10, 2015: CymaBay Therapeutics Announces the Initiation of a Phase 2 Study of MBX-8025 in Patients With Primary Biliary Cholangitis/Cirrhosis
      • Nov 09, 2015: NGM Bio to Present Data Highlighting the Therapeutic Potential of NGM282 in Cholestatic Liver Diseases at AASLD's The Liver Meeting 2015
      • Nov 03, 2015: Intercept Announces Data to be Presented at the 2015 AASLD Annual Meeting
      • Aug 31, 2015: FDA Grants Priority Review for Intercept's Obeticholic Acid for the Treatment of Primary Biliary Cirrhosis
      • Jun 29, 2015: Intercept Pharmaceuticals Submits Applications in the U.S. and Europe for Marketing Approval of Obeticholic Acid for the Treatment of Primary Biliary Cirrhosis
      • Apr 13, 2015: Intercept Announces New Data in PBC and NASH to be Presented at EASL 2015
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Primary Biliary Cirrhosis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Primary Biliary Cirrhosis - Pipeline by AlbireoPharma, H2 2016
  • Primary Biliary Cirrhosis - Pipeline by CymaBay Therapeutics, Inc., H2 2016
  • Primary Biliary Cirrhosis - Pipeline by Dr. Falk Pharma GmbH, H2 2016
  • Primary Biliary Cirrhosis - Pipeline by Enanta Pharmaceuticals, Inc., H2 2016
  • Primary Biliary Cirrhosis - Pipeline by Genextra S.p.a., H2 2016
  • Primary Biliary Cirrhosis - Pipeline by GenKyoTex S.A., H2 2016
  • Primary Biliary Cirrhosis - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Primary Biliary Cirrhosis - Pipeline by MediGene AG, H2 2016
  • Primary Biliary Cirrhosis - Pipeline by NGM Biopharmaceuticals, Inc., H2 2016
  • Primary Biliary Cirrhosis - Pipeline by Novartis AG, H2 2016
  • Primary Biliary Cirrhosis - Pipeline by Shire Plc, H2 2016
  • Primary Biliary Cirrhosis - Pipeline by TGV-Laboratories, H2 2016
  • Primary Biliary Cirrhosis - Pipeline by Virobay Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Primary Biliary Cirrhosis - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Primary Biliary Cirrhosis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top